India, Sept. 11 -- Alembic Pharmaceuticals on Friday announced that its bioequivalence facility in Vadodara, Gujarat, has successfully cleared an unannounced inspection by the US Food and Drug Administration (USFDA) with zero observations.
The onsite inspection was conducted by the US regulator from August 31 to September 10, 2026, as part of its review of the company's bioequivalence facility.
The inspection concluded without any Form 483 observations, according to the company's regulatory filing.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....